Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats

Nanotoxicology

Volumn 11, Issue 2, 2017, Pages 210-222

  Cheah, Hoay Yan ^a   Šarenac, Olivera ^b   Arroyo, Juan J ^c   Vasić, Marko ^b   Lozić, Maja ^b   Glumac, Sofija ^b   Hoe, See Ziau ^a   Hindmarch, Charles Colin Thomas ^a,d   Murphy, David ^e   Kiew, Lik Voon ^a   Lee, Hong Boon ^a   Vicent, María J ^c   Chung, Lip Yong ^a   Japundžić Žigon, Nina ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^d Univeristy of Kingston   (Canada)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

cardiotoxicity; echocardiography; Nanomaterials; polymer carriers; telemetry

Indexed keywords

CASPASE 3; COPOLYMER; DOXORUBICIN; N (2 HYDROXYPROPYL)METHYLACRYLAMIDE COPOLYMER; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; N-(2-HYDROXYPROPYL)METHACRYLAMIDE; N-(2-HYDROXYPROPYL)METHACRYLAMIDE CO-POLYMER-DOXORUBICIN CONJUGATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE VARIABILITY; BODY WEIGHT; CACHEXIA; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISPERSITY; DRUG CONJUGATION; ECHOCARDIOGRAPHY; GLOMERULOSCLEROSIS; HEART FAILURE; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RATE VARIABILITY; HEART TISSUE; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; IN VIVO STUDY; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; LIVER NECROSIS; LUNG CONGESTION; LUNG HEMORRHAGE; MALE; MEAN ARTERIAL PRESSURE; MOLECULAR WEIGHT; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PULSE PRESSURE; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SURVIVAL RATE; TELEMETRY; TREATMENT DURATION; ANIMAL; BLOOD PRESSURE; CARDIAC MUSCLE; DRUG EFFECTS; HEART; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MOUSE; PATHOLOGY; RANDOMIZATION; SURVIVAL ANALYSIS; WISTAR RAT;

ACRYLAMIDES; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CARDIOTOXICITY; DOXORUBICIN; ECHOCARDIOGRAPHY; HEART; HEART RATE; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MYOCARDIUM; RANDOM ALLOCATION; RATS; RATS, WISTAR; SURVIVAL ANALYSIS; TELEMETRY;

EID: 85012050573     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.1080/17435390.2017.1285071     Document Type: Article

References (48)

1. Algren DA, Ashworth A., 2015. Acute acepromazine overdose:clinical effects and toxicokinetic evaluation. J Med Toxicol 11:121–3.
2. Bertinchant J, Polge A, Juan J, Oliva-Lauraire M, Giuliani I, Marty-Double C, et al. 2003. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta 329:39–51.
3. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. 2004. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749–54.
4. Chatterjee K, Zhang J, Honbo N, Karliner JS., 2010. Doxorubicin cardiomyopathy. Cardiology 115:155–62.
5. Cohen-Segev R, Francis B, Abu-saleh N, Awad H, Lazarovich A, Kabala A, et al. 2014. Cardiac and renal distribution of ACE and ACE-2 in rats with heart failure. Acta Histochem 116:1342–9.
6. Curigliano G, Cardinale D, Suter T, Plataniotis G, De Azambuja E, Sandri MT, et al. 2012. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy:ESMO Clinical Practice Guidelines. Ann Oncol 23:vii155–66.
7. Dharmani M, Mustafa MR, Achike FI, Sim M-K., 2007. Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. Eur J Pharmacol 561:144–50.
8. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M., 2008. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity. Am J Clin Pathol 130:688–95.
9. Drawz PE, Babineau DC, Brecklin C, HE J, Kallem RR, Soliman EZ, et al. 2013. Heart rate variability is a predictor of mortality in chronic kidney disease:a report from the CRIC Study. Am J Nephrol 38:517–28.
10. Duncan R, Coatsworth JK, Burtles S., 1998. Preclinical toxicology of a novel polymeric antitumour agent:HPMA copolymer doxorubicin (PK1). Hum Exp Toxicol 17:93–104.
11. Duncan R, Vicent MJ., 2010. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev 62:272–82.
12. Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F., 2014. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol 28:31.
13. Fox ME, Szoka FC, Fréchet JMJ., 2009. Soluble polymer carriers for the treatment of cancer:the importance of molecular architecture. Acc Chem Res 42:1141–51.
14. Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, et al. 2013. Activation of the Mas receptor by angiotensin-(1–7) in the renin–angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 145:874–84.
15. Haddadian Z, Eftekhari G, Mazloom R, Jazaeri F, Dehpour AR, Mani AR., 2013. Effect of endotoxin on heart rate dynamics in rats with cirrhosis. Auton Neurosci 177:104–13.
16. Hanton G, Eder V, Rochefort G, Bonnet P, Hyvelin JM., 2008. Echocardiography, a non-invasive method for the assessment of cardiac function and morphology in preclinical drug toxicology and safety pharmacology. Exp Opin Drug Metab Toxicol 4:681–96.
17. Hopewell WJ, Duncan R, Wilding D, Chakrabarti K., 2001. Preclinical evaluation of the cardiotoxicity of PK2:a novel HPMA copolymer–doxorubicin–galactosamine conjugate antitumour agent. Hum Exp Toxicol 20:461–70.
18. Japundzic N, Grichois ML, Zitoun P, Laude D, Elghozi JL., 1990. Spectral analysis of blood pressure and heart rate in conscious rats:effects of autonomic blockers. J Auton Nerv Syst 30:91–100.
19. Japundzic-Zigon N., 1998. Physiological mechanisms in regulation of blood pressure fast frequency variations. Clin Exp Hypertens 20:359–88.
20. Katzung BG, Masters SB, Trevor AJ., 2004. Basic and Clinical Pharmacology. New York, NY:Lange Medical Books/McGraw-Hill.
21. Kedar U, Phutane P, Shidhaye S, Kadam V., 2010. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 6:714–29.
22. Kopeček J, Kopečková P, Minko T, Lu ZR., 2000. HPMA copolymer–anticancer drug conjugates:design, activity, and mechanism of action. Eur J Pharm Biopharm 50:61–81.
23. Kopeček J, Šprincl L, Lim D., 1973. New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood. J Biomed Mater Res 7:179–91.
24. Lee VW, Harris DC., 2011. Adriamycin nephropathy:a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 16:30–8.
25. Lončar-Turukalo T, Vasi? M, Tasi? T, Mijatovi? G, Glumac S, Baji? D, T, Vasić M, Tasić T, Mijatović G, Glumac S, Bajić D, et al. 2015. Heart rate dynamics in doxorubicin-induced cardiomyopathy. Physiol Meas 36:727–39.
26. López-Miranda V, Herradon E, González C, Isabel Martin M., 2010. Vascular toxicity of chemotherapeutic agents. Curr Vasc Pharmacol 8:692–700.
27. Malugin A, Kopečková P, Kopeček J., 2007. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J Control Release 124:6–10.
28. Mani AR, Montagnese S, Jackson CD, Jenkins SCW, Head IM, Stephens RC, et al. 2009. Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 296:G330–8.
29. Miltenburg N, Boogerd W., 2014. Chemotherapy-induced neuropathy:a comprehensive survey. Cancer Treat Rev 40:872–82.
30. Mitry MA, Edwards JG., 2016. Doxorubicin induced heart failure:phenotype and molecular mechanisms. Int J Cardiol Heart Vasc 10:17–24.
31. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL., 2012. Doxorubicin-induced cardiomyopathy:from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–25.
32. Patel VB, Zhong J-C, Grant MB, Oudit GY., 2016. Role of the ACE2/Angiotensin 1–7 axis of the renin–angiotensin system in heart failure. Circ Res 118:1313–26.
33. Ponikowski P, Anker SD, Chua TP, Szelemej JR, Piepoli M, Adamopoulos S, et al. 1997. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 79:1645–50.
34. Ranpuria R, Hall M, Chan CT, Unruh M., 2008. Heart rate variability (HRV) in kidney failure:measurement and consequences of reduced HRV. Nephrol Dial Transplant 23:444–9.
35. Šarenac O, Lozić M, Drakulić S, Bajić D, Paton JF, Murphy D, et al. 2011. Autonomic mechanisms underpinning the stress response in borderline hypertensive rats. Exp Physiol 96:574–89.
36. Sawaya H, Sebag IA, Plana JC, Januzzi JL, KY B, Cohen V, et al. 2011. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107:1375–80.
37. Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, et al. 2009. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 34:1629–36.
38. Sipola P, Vanninen E, Jantunen E, Nousiainen T, Kiviniemi M, Hartikainen J, et al. 2012. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy. Nucl Med Commun 33:51–9.
39. Stein AB, Tiwari IS, Thomas P, Hunt G, Levent C, Stoddard MF, et al. 2007. Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. Basic Res Cardiol 102:28–41.
40. Stojičić S, Milutinović-Smiljanić S, Šarenac O, Milosavljević S, Paton JF, Murphy D, et al. 2008. Blockade of central vasopressin receptors reduces the cardiovascular response to acute stress in freely moving rats. Neuropharmacology 54:824–36.
41. Stuckey MI, Petrella RJ., 2013. Heart rate variability in type 2 diabetes mellitus. Crit Rev Biomed Eng 41:137–47.
42. Teraoka K, Hirano M, Yamaguchi K, Yamashina A., 2000. Progressive cardiac dysfunction in adriamycin‐induced cardiomyopathy rats. Eur J Heart Fail 2:373–8.
43. Tomalova AB, Sirova M, Rossmann P, Pola R, Strohalm J, Chytil P, et al. 2016. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia. J Control Release 223:1–10.
44. Tong J, Ganguly P, Singal P., 1991. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 260:H909–16.
45. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. 1999. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]:first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5:83–94.
46. Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, Duncan R., 2005. Polymer therapeutics designed for a combination therapy of hormone‐dependent cancer. Angewandte Chemie 117:4129–34.
47. Yeung TK, Hopewell JW, Simmonds RH, Seymour LW, Duncan R, Bellini O, et al. 1991. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl) methacrylamide conjugates:and experimental study in the rat. Cancer Chemother Pharmacol 29:105–11.
48. Yokoyama M., 2014. Polymeric micelles as drug carriers:their lights and shadows. J Drug Target 22:576–83.